Spark offers outcomes-based rebates for gene therapy

Spark Therapeutics Inc has set the price per patient of its new gene therapy for retinal dystrophy at $850,000 but at the same time opened negotiations with leading US insurers to link payments with the success of the treatment.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States